Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 53OTHER 52NIH 10OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Standard of Care 6Cisplatin 6Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4toripalimab 3pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Prednisone 3Population Groups 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × trastuzumab deruxtecan × 1 year × Clear all
NCT07416253 2026-02-18

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Henan Cancer Hospital

Phase 2 Not yet recruiting
68 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡